BioSpace News Archive

Mount Sinai researchers have discovered a key mechanism for how this occurs in breast cancer. For that and more research stories, continue reading.

The alliance will pair AbbVie’s neuroscience capabilities with Plexium’s comprehensive TPD platform.

Alexion shared the news that Ultomiris (ravulizumab-cwvz) has been approved by the FDA for commercialization, adding another indication for the precedent-setting drug.

Moderna has made the official request to the FDA to approve its COVID-19 for use in children ages 6 months to 5 years. Moderna also announced the location of its first non-U.S. mRNA manufacturing facility.

Boston-based Kelonia Therapeutics launched after a successful $50 million Series A round of financing, which will push its research efforts in genetic medicines for immunology and oncology.

Alnylam announced another delay, this one caused by a much more sinister reason – the invasion of Ukraine, now heading into its third month and causing disruption on a multi-faceted and global scale.

GC Biopharma and Acuitas Therapeutics announced that they have entered into a Development and Option agreement for Acuitas’ LNP technology.

The Combined Shareholders Meeting of Pixium Vision SA was held in Paris on on April 19, 2022 and adopted all the resolutions put to the vote relating to the granting to the Board of financial delegations, of delegations and authorisations allowing the allocation of equity warrants, free shares and stock options and relating to the maximum amount to be allocated to the directors as compensation for their activities.

Vifor Fresenius Medical Care Renal Pharma and Cara Therapeutics, Inc. announced that the European Commission has granted marketing authorization to Kapruvia® for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult hemodialysis patients.

Sedana Medical AB announces that the first patient has been enrolled in the company’s US clinical studies.